A Spot of Dividends: Two Stocks for the Long Haul

Johnson & Johnson and Merck, you see, are rather large players in the pharmaceutical game. Merck, in particular, has made a name for itself with a rather clever concoction called Keytruda, a remedy for a most unpleasant ailment that seems to be causing quite a stir. It’s currently the best-selling cancer drug, and they’ve managed to apply it to a positively alarming number of cancers – a truly impressive feat, wouldn’t you say? And they’re not resting on their laurels, oh no. They’re diligently concocting new applications, which should keep the coffers full even when the original patent expires in 2028 – a bit like a resourceful butler always having a plan B.








